• Something wrong with this record ?

Standardization of Sequencing Coverage Depth in NGS: Recommendation for Detection of Clonal and Subclonal Mutations in Cancer Diagnostics

A. Petrackova, M. Vasinek, L. Sedlarikova, T. Dyskova, P. Schneiderova, T. Novosad, T. Papajik, E. Kriegova,

. 2019 ; 9 (-) : 851. [pub] 20190904

Language English Country Switzerland

Document type Journal Article

Grant support
NV16-32339A MZ0 CEP Register

The insufficient standardization of diagnostic next-generation sequencing (NGS) still limits its implementation in clinical practice, with the correct detection of mutations at low variant allele frequencies (VAF) facing particular challenges. We address here the standardization of sequencing coverage depth in order to minimize the probability of false positive and false negative results, the latter being underestimated in clinical NGS. There is currently no consensus on the minimum coverage depth, and so each laboratory has to set its own parameters. To assist laboratories with the determination of the minimum coverage parameters, we provide here a user-friendly coverage calculator. Using the sequencing error only, we recommend a minimum depth of coverage of 1,650 together with a threshold of at least 30 mutated reads for a targeted NGS mutation analysis of ≥3% VAF, based on the binomial probability distribution. Moreover, our calculator also allows adding assay-specific errors occurring during DNA processing and library preparation, thus calculating with an overall error of a specific NGS assay. The estimation of correct coverage depth is recommended as a starting point when assessing thresholds of NGS assay. Our study also points to the need for guidance regarding the minimum technical requirements, which based on our experience should include the limit of detection (LOD), overall NGS assay error, input, source and quality of DNA, coverage depth, number of variant supporting reads, and total number of target reads covering variant region. Further studies are needed to define the minimum technical requirements and its reporting in diagnostic NGS.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035649
003      
CZ-PrNML
005      
20191011114912.0
007      
ta
008      
191007s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fonc.2019.00851 $2 doi
035    __
$a (PubMed)31552176
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Petrackova, Anna $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia.
245    10
$a Standardization of Sequencing Coverage Depth in NGS: Recommendation for Detection of Clonal and Subclonal Mutations in Cancer Diagnostics / $c A. Petrackova, M. Vasinek, L. Sedlarikova, T. Dyskova, P. Schneiderova, T. Novosad, T. Papajik, E. Kriegova,
520    9_
$a The insufficient standardization of diagnostic next-generation sequencing (NGS) still limits its implementation in clinical practice, with the correct detection of mutations at low variant allele frequencies (VAF) facing particular challenges. We address here the standardization of sequencing coverage depth in order to minimize the probability of false positive and false negative results, the latter being underestimated in clinical NGS. There is currently no consensus on the minimum coverage depth, and so each laboratory has to set its own parameters. To assist laboratories with the determination of the minimum coverage parameters, we provide here a user-friendly coverage calculator. Using the sequencing error only, we recommend a minimum depth of coverage of 1,650 together with a threshold of at least 30 mutated reads for a targeted NGS mutation analysis of ≥3% VAF, based on the binomial probability distribution. Moreover, our calculator also allows adding assay-specific errors occurring during DNA processing and library preparation, thus calculating with an overall error of a specific NGS assay. The estimation of correct coverage depth is recommended as a starting point when assessing thresholds of NGS assay. Our study also points to the need for guidance regarding the minimum technical requirements, which based on our experience should include the limit of detection (LOD), overall NGS assay error, input, source and quality of DNA, coverage depth, number of variant supporting reads, and total number of target reads covering variant region. Further studies are needed to define the minimum technical requirements and its reporting in diagnostic NGS.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vasinek, Michal $u Department of Computer Science, Faculty of Electrical Engineering and Computer Science, Technical University of Ostrava, Ostrava, Czechia.
700    1_
$a Sedlarikova, Lenka $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia.
700    1_
$a Dyskova, Tereza $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia.
700    1_
$a Schneiderova, Petra $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia.
700    1_
$a Novosad, Tomas $u Department of Computer Science, Faculty of Electrical Engineering and Computer Science, Technical University of Ostrava, Ostrava, Czechia.
700    1_
$a Papajik, Tomas $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia.
700    1_
$a Kriegova, Eva $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia.
773    0_
$w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 9, č. - (2019), s. 851
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31552176 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191011115332 $b ABA008
999    __
$a ind $b bmc $g 1452309 $s 1074199
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 9 $c - $d 851 $e 20190904 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
GRA    __
$a NV16-32339A $p MZ0
LZP    __
$a Pubmed-20191007

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...